Quinine Sulfate for Muscle/Leg Cramps - Off-Label Bedtime Use

1 El-Tawil et al. 2010 — Quinine for Muscle Cramps (COCHRANE)

(El-Tawil et al. 2010)

Full Citation:: El-Tawil S, Al Musa T, Valli H, Lunn MP, El-Tawil T, Weber M. Quinine for muscle cramps. Cochrane Database of Systematic Reviews. 2010;(12):CD005044. DOI:: 10.1002/14651858.CD005044.pub2 PMID:: 21154358 Study Design:: Cochrane systematic review and meta-analysis of randomized controlled trials (all causes and locations of muscle cramps) Sample Size:: 1586 participants across 23 trials Key Findings::

• Quinine has been used to treat cramps of all causes, but controversy continues about its efficacy and safety.
• Found only limited evidence of benefit for quinine in reducing muscle cramps.
• Risk–benefit balance judged unfavourable given the documented adverse events. Conclusion:: The evidence for quinine in muscle cramps is limited and does not justify routine off-label use given the safety concerns. Limitations:: Older trials, heterogeneous cramp causes; did not resolve the benefit/harm trade-off. Certainty Assessment:: 0.75 raw × 0.75 general population weight = discounted 0.56

2 Man-Son-Hing & Wells 1995 — Meta-Analysis of Quinine for Nocturnal Leg Cramps in Elderly (BMJ)

(Man-Son-Hing and Wells 1995)

Full Citation:: Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ. 1995;310(6971):13–17. PMID:: 7827545 Study Design:: Meta-analysis of 6 randomized, double-blind, crossover trials Sample Size:: 107 ambulatory elderly patients with regular nocturnal leg cramps Key Findings::

• Quinine significantly reduced the number of cramps over 4 weeks vs placebo (8.83 fewer cramps; 95% CI 4.16 to 13.49).
• Reduced the number of nights with cramps by 27.4%. Conclusion:: Quinine shows efficacy for nocturnal leg cramps in elderly patients, but the meta-analysis does not resolve the safety question. Limitations:: Small total sample; elderly ambulatory population only; published-data bias not addressed; pre-boxed-warning era. Certainty Assessment:: 0.55 raw × 0.75 general population weight = discounted 0.41

3 Man-Son-Hing et al. 1998 — Quinine for Nocturnal Leg Cramps Including Unpublished Data (JGIM)

(Man-Son-Hing, Wells, and Lau 1998)

Full Citation:: Man-Son-Hing M, Wells G, Lau A. Quinine for nocturnal leg cramps: a meta-analysis including unpublished data. Journal of General Internal Medicine. 1998;13(9):600–606. PMID:: 9754515 Study Design:: Meta-analysis of 8 randomized, double-blind, placebo-controlled trials (4 published + 4 unpublished; 7 crossover) Sample Size:: 659 ambulatory patients with regular nocturnal leg cramps Key Findings::

• Pooling all crossover studies, patients had 3.60 fewer cramps per 4-week period on quinine vs placebo (95% CI 2.15 to 5.05).
• This is lower than the 8.83 estimate from the earlier published-data-only meta-analysis. Conclusion:: Adding unpublished data materially reduces the apparent benefit, indicating publication bias inflates the published-only estimate. The true benefit is small. Limitations:: Residual unpublished-data availability uncertainty; no harm data; pre-boxed-warning era. Certainty Assessment:: 0.60 raw × 0.75 general population weight = discounted 0.45

4 Young 2009 — Leg Cramps (BMJ CLINICAL EVIDENCE)

(Young 2009)

Full Citation:: Young G. Leg cramps. BMJ Clinical Evidence. 2009;2009:1113. PMID:: 19445755 Study Design:: BMJ Clinical Evidence systematic review of treatments for idiopathic and pregnancy-related leg cramps Sample Size:: 12 systematic reviews, RCTs, or observational studies Key Findings::

• Reviewed treatments for idiopathic leg cramps and pregnancy-related leg cramps.
• Treatments generally lack proof of efficacy.
• Included harms alerts from the US FDA and UK MHRA concerning quinine. Conclusion:: Standard leg-cramp treatments have limited evidence; quinine’s use is explicitly complicated by regulatory harm alerts. Limitations:: Clinical Evidence format (updated periodically); limited direct trial detail. Certainty Assessment:: 0.50 raw × 0.75 general population weight = discounted 0.38

5 Liles et al. 2016 — Diversity and Severity of Adverse Reactions to Quinine (AM J HEMATOL; PRIMARY HARM)

(Liles et al. 2016)

Full Citation:: Liles NW, Page EE, Liles AL, Vesely SK, Raskob GE, George JN. Diversity and severity of adverse reactions to quinine: a systematic review. American Journal of Hematology. 2016;91(5):461–466. DOI:: 10.1002/ajh.24314 PMID:: 26822544 Study Design:: Systematic review of 114 articles; three reviewers independently evaluated evidence for causal association Sample Size:: 114 articles with sufficient data Key Findings::

• Quinine is a common cause of drug-induced thrombocytopenia and the most common cause of drug-induced thrombotic microangiopathy.
• Broad spectrum of immune-mediated and toxic adverse reactions across organ systems.
• Documented source of quinine exposure, organ systems involved, severity, and patient outcomes. Conclusion:: Quinine’s adverse-reaction spectrum is diverse and often severe; this underlies the FDA boxed warning and restriction of off-label cramps use. Limitations:: Case-report-derived; levels-of-evidence assessment; retrospective. Certainty Assessment:: 0.80 raw × 0.75 general population weight = discounted 0.60

6 Haeusler et al. 2018 — Arrhythmogenic Cardiotoxicity of Quinoline Antimalarials (BMC MED)

(Haeusler et al. 2018)

Full Citation:: Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Medicine. 2018;16(1):200. DOI:: 10.1186/s12916-018-1188-2 PMID:: 30400791 Study Design:: Systematic review of cardiovascular side effects of the quinoline and structurally related antimalarial class Key Findings::

• Quinoline antimalarials (including quinine) are associated with hypotension and electrocardiographic QT-interval prolongation.
• Prolonged QT is a sensitive but non-specific risk marker for Torsade de Pointes, a potentially lethal ventricular arrhythmia. Conclusion:: Quinoline-class drugs carry arrhythmogenic cardiovascular risk; relevant to quinine’s off-label use, especially with QT-prolonging co-medications. Limitations:: Class-level review; QT risk is context-dependent; antimalarial-dosing focus. Certainty Assessment:: 0.70 raw × 0.75 general population weight = discounted 0.53

7 White 2007 — Cardiotoxicity of Antimalarial Drugs (LANCET INFECT DIS)

(White 2007)

Full Citation:: White NJ. Cardiotoxicity of antimalarial drugs. The Lancet Infectious Diseases. 2007;7(8):549–558. PMID:: 17646028 Study Design:: Authoritative narrative review of cardiovascular effects of antimalarial drug classes Key Findings::

• Among antimalarials, only the quinoline and structurally related class has clinically significant cardiovascular effects.
• Quinine can exacerbate orthostatic hypotension and delays ventricular depolarization (class 1c effect).
• Quinidine and halofantrine have clinically significant repolarization effects (class 3) causing dangerous QT prolongation. Conclusion:: Quinine contributes hypotension and mild depolarization delay; the class as a whole carries cardiovascular risk relevant to dysautonomic and cardiac-comorbid patients. Limitations:: Narrative review; antimalarial (acute-illness) dosing context. Certainty Assessment:: 0.70 raw × 0.75 general population weight = discounted 0.53

8 Spillane et al. 2025 — Drug Treatment for Myotonia (COCHRANE; COMPETING-CLASS MECHANISM)

(Spillane et al. 2025)

Full Citation:: Spillane J, Trip J, Drost G, Faber CG, Hanna MG, Nevitt SJ, Vivekanandam V. Drug treatment for myotonia. Cochrane Database of Systematic Reviews. 2025;(4):CD004762. DOI:: 10.1002/14651858.CD004762.pub3 PMID:: 40197813 Study Design:: Cochrane systematic review of drug treatment for myotonia (non-dystrophic and dystrophic) Key Findings::

• Myotonia manifests as stiffness, cramps, locking, pain, and fatigue.
• Sodium-channel blockers, tricyclic antidepressants, benzodiazepines, calcium antagonists, taurine, and prednisone may reduce myotonia. Conclusion:: Sodium-channel blockers are the established drug class that modulates cramp/myotonia muscle-excitability — the same mechanistic class quinine partially mimics, providing competing-treatment and mechanism context. Limitations:: Myotonic disorders (channelopathies) rather than idiopathic cramps; mixed evidence quality. Certainty Assessment:: 0.70 raw × 0.50 other-disease-model weight = discounted 0.35

9 Hawke et al. 2021 — Non-Drug Therapies for Lower Limb Muscle Cramps (COCHRANE; NULL CONTEXT)

(Hawke et al. 2021)

Full Citation:: Hawke F, Sadler SG, Katzberg HD, Pourkazemi F, Chuter V, Burns J. Non-drug therapies for the secondary prevention of lower limb muscle cramps. Cochrane Database of Systematic Reviews. 2021;(5):CD008496. DOI:: 10.1002/14651858.CD008496.pub3 PMID:: 33998664 Study Design:: Cochrane systematic review (update) of non-drug, non-invasive therapies for lower limb muscle cramps Key Findings::

• Many interventions for lower limb cramps are controversial or could cause harm.
• Often people experience no benefit from the interventions used.
• Overall limited quality of evidence for non-drug cramp therapies. Conclusion:: No well-validated non-drug replacement exists for marginal drug options — quinine persists in use partly because effective alternatives are lacking. Limitations:: Limited/heterogeneous trials; several common interventions unsupported. Certainty Assessment:: 0.70 raw × 0.75 general population weight = discounted 0.53

10 Torbergsen et al. 2015 — Painful Cramps in Nav1.4-G1306A Mutation (MUSCLE NERVE; INDIRECT ION-CHANNEL LINK)

(Torbergsen et al. 2015)

Full Citation:: Torbergsen T, Jurkat-Rott K, Stålberg EV, Løseth S, Hødneø A, Lehmann-Horn F. Painful cramps and giant myotonic discharges in a family with the Nav1.4-G1306A mutation. Muscle & Nerve. 2015;52(4):680–683. DOI:: 10.1002/mus.24672 PMID:: 26080010 Study Design:: Family genetics study; SCN4A/CLCN1 sequencing; clinical and neurophysiological characterization Sample Size:: One Norwegian family (plus comparison across 21 G1306A families) Key Findings::

• A G1306A mutation in the Nav1.4 voltage-gated skeletal-muscle sodium channel (SCN4A) was identified.
• This family uniquely exhibited painful muscle cramps and giant myotonic discharges.
• Proposes ephaptic transmission between neighboring muscle fibers to explain the unusual discharge size. Conclusion:: Skeletal-muscle sodium-channel (Nav1.4) dysfunction directly produces painful cramps and myotonia — the channel-level mechanism relevant to quinine’s anti-cramp action and to the ME/CFS muscle-ion-channel hypothesis. Limitations:: Single-family index; channelopathy (genetic) rather than idiopathic cramps or ME/CFS; indirect relevance to quinine pharmacology. Certainty Assessment:: 0.50 raw × 0.50 other-disease-model weight = discounted 0.25

11 Earl et al. 2017 — Vitamin D Status in CFS/ME (NULL; Direct)

(Earl et al. 2017)

Full Citation:: Earl KE, Sakellariou GK, Sinclair M, et al. Vitamin D status in chronic fatigue syndrome/myalgic encephalomyelitis: a cohort study from the North-West of England. BMJ Open. 2017;7(11):e015296. DOI:: 10.1136/bmjopen-2016-015296 Study Design:: Cohort study; n=92 CFS/ME, n=94 age-matched healthy controls; LC-MS/MS Key Findings::

• No evidence of vitamin D deficiency in CFS/ME; total 25(OH)D significantly HIGHER in patients (60.2 vs 47.3 nmol/L, p=0.001).
• Higher vitamin D driven by greater supplement use in the CFS/ME group.
• No association between Chalder fatigue score and vitamin D level. Conclusion:: Directly contradicts the MEA assumption that housebound ME/CFS patients are vitamin-D deficient. Supplementation in this cohort already elevated levels; routine high-dose vitamin D for fatigue lacks supporting evidence. Limitations:: Single region (NW England); cross-sectional; supplementation confounds natural status; does not exclude deficiency in a more severe, truly housebound subset. Certainty Assessment:: 0.80 raw × 1.0 ME/CFS direct population weight = discounted 0.80 (NULL evidence)

12 Rolvien & Amling 2022 — Disuse Osteoporosis (Bedrest Precedent)

(Rolvien and Amling 2022)

Full Citation:: Rolvien T, Amling M. Disuse osteoporosis: clinical and mechanistic insights. Calcified Tissue International. 2022;110(5):592–604. DOI:: 10.1007/s00223-021-00836-1 Study Design:: Peer-reviewed clinical + mechanistic review Key Findings::

• Immobilization/bed rest causes immediate trabecular and cortical bone loss, increased resorption and decreased formation.
• Osteocytes sense mechanical load via mechanosensors (Piezo1, primary cilia, connexin hemichannels); unloading raises sclerostin, suppressing formation.
• Settings: spinal cord injury, neurological/neuromuscular disorders, fracture immobilization, bed rest. Conclusion:: Sustained mechanical unloading — the situation in moderate–severe ME/CFS — is a direct driver of osteoporosis, supporting the reduced-mobility risk hypothesis (H1). Limitations:: Not ME/CFS-specific; extrapolation from disuse/SCI populations; no dose-response to degree of inactivity given. Certainty Assessment:: 0.78 raw × 0.50 other-disease-model weight = discounted 0.39

13 Qin et al. 2013 — Muscle Contraction, RANKL/OPG and Bone (Indirect Biochemical)

(Qin et al. 2013)

Full Citation:: Qin W, Sun L, Cao J, et al. The central nervous system (CNS)-independent anti-bone-resorptive activity of muscle contraction and the underlying molecular and cellular signatures. Journal of Biological Chemistry. 2013;288(19):13511–13521. DOI:: 10.1074/jbc.M113.454892 Study Design:: Animal model (SCI rat); electrical-stimulation muscle contraction Key Findings::

• Stimulated muscle contraction reversed SCI-induced serum CTX rise and reduced osteoclast numbers.
• Raised OPG/RANKL ratio; lowered Wnt inhibitors (DKK1, sFRP2, sclerostin).
• Anti-resorptive effect independent of the CNS, via mechanical + myokine signals. Conclusion:: Reduced muscle contraction/loading shifts OPG/RANKL toward bone resorption. Maps the RANKL/OPG pathway to ME/CFS deconditioning: muscle dysfunction plus inactivity predisposes to bone loss. Limitations:: Animal model; SCI (acute paralysis) not equivalent to ME/CFS; indirect applicability. Certainty Assessment:: 0.55 raw × 0.35 other-disease-model weight = discounted 0.19

14 Hart 2021 — Deconditioning and the “Use It or Lose It” Principle

(Hart 2021)

Full Citation:: Hart DA. Learning from human responses to deconditioning environments: improved understanding of the “use it or lose it” principle. Frontiers in Sports and Active Living. 2021;3:685845. DOI:: 10.3389/fspor.2021.685845 Study Design:: Narrative review (spaceflight, bed rest, protracted sedentary behavior) Key Findings::

• Musculoskeletal and cardiovascular systems require constant reinforcement; chronic deconditioning causes systemic loss.
• Chronic deconditioning poses risk for disease development and progression, including bone loss. Conclusion:: Provides the conceptual frame for the H1 claim: prolonged reduced activity in moderate–severe ME/CFS leads to deconditioning with bone consequences. Limitations:: Narrative/opinion; broad scope; not ME/CFS-specific; no quantitative risk estimates. Certainty Assessment:: 0.55 raw × 0.40 other-disease-model weight = discounted 0.22

15 Shane et al. 2014 — Atypical Femur Fractures and Bisphosphonates (HARM)

(Shane et al. 2014)

Full Citation:: Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2014;29(1):1–23. DOI:: 10.1002/jbmr.1998 Study Design:: ASBMR Task Force report / consensus Key Findings::

• Atypical femur fractures (AFFs) significantly associated with long-term bisphosphonate and denosumab use.
• Absolute risk low (3.2–50 per 100,000 person-years) but ~100 per 100,000 with long-term use.
• Suppression of intracortical remodeling impairs stress-fracture healing; risk declines after stopping. Conclusion:: Long-term antiresorptive (alendronate/risedronate) use carries an AFF risk that must be weighed, especially when prolonged in a population with reduced weight-bearing load. Limitations:: Consensus; observational association; absolute risk low; not ME/CFS-specific. Certainty Assessment:: 0.80 raw × 0.50 other-disease-model weight = discounted 0.40 (HARM)

16 Bolland et al. 2010 — Calcium Supplements and Cardiovascular Risk (HARM)

(Bolland et al. 2010)

Full Citation:: Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691. DOI:: 10.1136/bmj.c3691 Study Design:: Meta-analysis; patient-level (n=8151) and trial-level (n=11921) RCT data Key Findings::

• Calcium supplements without co-administered vitamin D increased MI risk (HR 1.31, 95% CI 1.02–1.67).
• Non-significant increases in stroke and composite cardiovascular endpoint. Conclusion:: Unsupplemented-calcium dosing carries modest cardiovascular risk. In ME/CFS with dysautonomic/cardiovascular comorbidity, calcium supplementation should not be assumed benign — a caution for the MEA prevention recommendation. Limitations:: Evidence for harm applies to calcium WITHOUT vitamin D; controversy and re-analysis followed publication; observational caveats. Certainty Assessment:: 0.72 raw × 0.50 other-disease-model weight = discounted 0.36 (HARM)

17 Taylor & Saag 2019 — Anabolic Bone Therapies: Safety (HARM; Side-Effect Overlap)

(Taylor and Saag 2019)

Full Citation:: Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evidence. 2019;14:41–50. DOI:: 10.2147/CE.S172820 Study Design:: Evidence-based review (teriparatide, abaloparatide, romosozumab) Key Findings::

• Teriparatide increases lumbar spine BMD vs placebo, alendronate, risedronate; fewer vertebral fractures than alendronate.
• Adverse effects: nausea, insomnia, flushing, myalgias, mild hypercalcemia/hyperuricemia.
• Rat osteosarcoma signal not replicated in humans or long-term pharmacovigilance. Conclusion:: Anabolic therapy adverse effects (myalgias, nausea, insomnia) overlap ME/CFS symptoms — supports the MEA trial-and-error caution and the difficulty of attributing new symptoms to drug vs disease. Limitations:: Focused on glucocorticoid-induced osteoporosis; not ME/CFS; teriparatide is a specialist second/third-line therapy. Certainty Assessment:: 0.72 raw × 0.40 other-disease-model weight = discounted 0.29 (HARM)

18 Arjunan et al. 2023 — Bisphosphonates: Pharmacology, Adverse Effects, Contraindications

(Arjunan et al. 2023)

Full Citation:: Arjunan D, Bhadada T, Mohankumar SB, Bhadada SK. Non-biological antiresorptive: bisphosphonates. Indian Journal of Orthopaedics. 2023;57(Suppl 1):120–126. DOI:: 10.1007/s43465-023-01054-7 Study Design:: Peer-reviewed narrative review Key Findings::

• Nitrogen-containing and non-nitrogenous bisphosphonates; mechanism, routes, dosing, drug holidays, adverse effects, contraindications.
• Oral bisphosphonates carry administration constraints (posture, esophageal irritation) relevant to severe/bedbound patients. Conclusion:: Provides the pharmacology and safety/contraindication context for alendronate/risedronate recommended in the MEA Q&A, including the oral-administration and tolerability challenges in bedbound patients. Limitations:: General review; not ME/CFS-specific; no patient-level safety data for chronic-illness populations. Certainty Assessment:: 0.60 raw × 0.40 other-disease-model weight = discounted 0.24

19 Bakheit et al. 1992 — Possible Upregulation of Hypothalamic 5-HT Receptors in Postviral Fatigue (BMJ)

(Bakheit et al. 1992)

Full Citation:: Bakheit AMO, Behan PO, Dinan TG, Gray CE, O’Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ. 1992;304(6833):1010–1012. DOI:: 10.1136/bmj.304.6833.1010 PMID:: 1586780 Study Design:: Small neuroendocrine challenge study (oral buspirone → prolactin) in postviral fatigue syndrome (PVFS) Key Findings::

• Oral buspirone (a 5-HT1A agonist that also blocks dopamine D2) stimulated prolactin release in PVFS patients.
• Findings interpreted as evidence consistent with upregulation of hypothalamic 5-hydroxytryptamine (5-HT) receptors.
• This is the first report linking buspirone-stimulated prolactin to serotonergic receptor changes in PVFS/ME. Conclusion:: Provides the original observation that buspirone-stimulated prolactin is altered in postviral fatigue, the ancestor finding of the prolactin-buspirone challenge line. Limitations:: Small sample; no depression control group; pre-Fukuda diagnostic era (PVFS clinical criteria); the buspirone probe also blocks dopamine D2, so the 5-HT interpretation is not unambiguous. Certainty Assessment:: 0.55 raw × 1.00 ME/CFS-cohort weight = discounted 0.55

20 Sharpe et al. 1996 — Increased Prolactin Response to Buspirone in CFS (J AFFECT DISORD; KEY REPLICATION)

(Sharpe et al. 1996)

Full Citation:: Sharpe M, Clements A, Hawton K, Young AH, Sargent P, Cowen PJ. Increased prolactin response to buspirone in chronic fatigue syndrome. Journal of Affective Disorders. 1996;41(1):71–76. DOI:: 10.1016/0165-0327(96)00075-4 PMID:: 8938208 Study Design:: Neuroendocrine challenge study; 11 male CFS patients vs matched healthy controls; buspirone 0.5 mg/kg orally Key Findings::

• CFS patients had significantly higher plasma prolactin and more nausea in response to buspirone than controls.
• The growth hormone response to buspirone did NOT distinguish CFS patients from controls.
• Authors question whether enhanced prolactin release reflects increased postsynaptic 5-HT1A sensitivity, and note prolactin is regulated by dopaminergic (D2) tone. Conclusion:: Independently replicates an exaggerated buspirone-stimulated prolactin response in CFS and explicitly flags the dopamine-D2 mechanism as an alternative to a pure 5-HT1A interpretation. Limitations:: Small, male-only sample; healthy controls only (no depression group); single-center; era of Fukuda criteria. Certainty Assessment:: 0.62 raw × 1.00 ME/CFS-cohort weight = discounted 0.62

21 Sharma et al. 2001 — Recovery from CFS Associated with Neuroendocrine Change (J R SOC MED)

(Sharma et al. 2001)

Full Citation:: Sharma A, Oyebode F, Kendall MJ, Jones PW. Recovery from chronic fatigue syndrome associated with changes in neuroendocrine function. Journal of the Royal Society of Medicine. 2001;94(1):26–27. DOI:: 10.1177/014107680109400107 PMID:: 11220065 Study Design:: Brief case/small-series report; buspirone challenge neuroendocrine assessment across recovery Key Findings::

• Clinical recovery from CFS was associated with changes in neuroendocrine function assessed by buspirone challenge.
• Suggests the neuroendocrine (prolactin) abnormality may track illness state rather than being a fixed trait. Conclusion:: Adds a longitudinal signal that the buspirone/prolactin abnormality may be state-dependent, supporting a challenge-test biomarker interpretation. Limitations:: Very small; brief-report format; limited methodological detail. Certainty Assessment:: 0.40 raw × 1.00 ME/CFS-cohort weight = discounted 0.40

22 Dinan et al. 2001 — Impact of Cortisol on Buspirone-Stimulated Prolactin (PSYCHONEUROENDOCRINOLOGY)

(Dinan et al. 2001)

Full Citation:: Dinan TG, Scott LV, Thakore J, Naesdal J, Keeling PW. Impact of cortisol on buspirone stimulated prolactin release: a double-blind placebo-controlled study. Psychoneuroendocrinology. 2001;26(7):751–756. DOI:: 10.1016/S0306-4530(01)00029-4 PMID:: 11500255 Study Design:: Double-blind placebo-controlled challenge study in healthy volunteers (n=50) Key Findings::

• Buspirone consistently elevated prolactin above placebo.
• Prolactin area-under-the-curve response correlated highly with baseline cortisol level. Conclusion:: Baseline glucocorticoid (HPA) state modulates the buspirone-stimulated prolactin response — directly relevant to interpreting CFS prolactin responses given documented CFS cortisol deficits. Limitations:: Healthy volunteers only (no ME/CFS); does not study the CFS population. Certainty Assessment:: 0.65 raw × 0.75 general-population weight = discounted 0.49

23 Yatham et al. 1995 — Neuroendocrine Assessment of 5-HT Function in CFS (CAN J PSYCHIATRY; NULL)

(Yatham et al. 1995)

Full Citation:: Yatham LN, Morehouse RL, Chisholm BT, Haase DA, MacDonald DD, Marrie TJ. Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome. Canadian Journal of Psychiatry. 1995;40(2):93–96. DOI:: 10.1177/070674379504000207 PMID:: 7788624 Study Design:: Serotonergic challenge study; 11 CFS patients vs 11 matched healthy controls; dl-fenfluramine 60 mg Key Findings::

• NO difference in baseline or fenfluramine-induced prolactin or cortisol responses between CFS patients and controls.
• No correlation between HAM-D depression scores and hormonal responses. Conclusion:: A global serotonergic (5-HT) hypersecretion model is NOT supported with fenfluramine; the exaggerated response appears probe-specific (fenfluramine differs from buspirone, which also blocks D2). Limitations:: Small sample; fenfluramine is a 5-HT releaser, not a D2 blocker, so it does not isolate the D2 mechanism; null result for this probe. Certainty Assessment:: 0.58 raw × 1.00 ME/CFS-cohort weight = discounted 0.58

24 Cleare & O’Keane 1996 — Re: Endocrine Responses to Fenfluramine Challenge in CFS (CAN J PSYCHIATRY)

(Cleare and O’Keane 1996)

Full Citation:: Cleare AJ, O’Keane V. Re: Endocrine responses to fenfluramine challenge in chronic fatigue syndrome. Canadian Journal of Psychiatry. 1996;41(2):129–131. PMID:: 8705960 Study Design:: Letter (commentary) on fenfluramine-challenge methodology in CFS Key Findings::

• Argues prior negative fenfluramine findings do not rule out serotonergic/neuroendocrine abnormalities in CFS.
• Clarifies conditions under which fenfluramine prolactin responses appear normal vs altered in CFS. Conclusion:: Corroborating methodological commentary on interpreting challenge-prolactin findings in CFS. Limitations:: Letter; no original patient data; no DOI registered. Certainty Assessment:: 0.35 raw × 1.00 ME/CFS-cohort weight = discounted 0.35

25 Newman et al. 1998 — Fenfluramine Challenge Test: A Critical Review (INT J NEUROPSYCHOPHARMACOL)

(Newman, Shapira, and Lerer 1998)

Full Citation:: Newman ME, Shapira B, Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. The International Journal of Neuropsychopharmacology. 1998;1(1):49–69. DOI:: 10.1017/S1461145798001072 PMID:: 11281946 Study Design:: Critical methodological review of the fenfluramine challenge test Key Findings::

• Prolactin response is dose-dependent, blocked by 5-HT2a/2c antagonists, negatively correlated with age, and increased in young females.
• Blunted prolactin responses predominate in major depression, but a significant minority of studies find no difference. Conclusion:: Provides the methodological caveats for interpreting serotonergic challenge results in CFS and depression — directly relevant to designing a modern replication study. Limitations:: Review of fenfluramine (not buspirone) methodology; not ME/CFS-specific. Certainty Assessment:: 0.68 raw × 0.75 general-population weight = discounted 0.51

26 Bearn et al. 1995 — Neuroendocrine Responses to d-Fenfluramine and Hypoglycemia in CFS (BIOL PSYCHIATRY)

(Bearn et al. 1995)

Full Citation:: Bearn J, Allain T, Coskeran P, Munro N, Butler J, McGregor A, Wessely S. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biological Psychiatry. 1995;37(4):245–252. DOI:: 10.1016/0006-3223(94)00121-i PMID:: 7711161 Study Design:: Neuroendocrine challenge in nondepressed CFS patients vs normal controls; d-fenfluramine + insulin-induced hypoglycemia Key Findings::

• Attenuated prolactin responses to insulin-induced hypoglycemia in CFS.
• No enhanced fenfluramine-prolactin response reported (contrasts with buspirone findings).
• Greater ACTH response / higher peak ACTH in CFS. Conclusion:: Prolactin regulation is perturbed in CFS, but the direction depends on the probe and neural pathway (hypoglycemia/PRL vs serotonergic/PRL vs D2), reinforcing that challenge-probe selection determines the signal. Limitations:: d-fenfluramine probe; does not isolate the D2 mechanism; small sample. Certainty Assessment:: 0.60 raw × 1.00 ME/CFS-cohort weight = discounted 0.60

27 Cleare et al. 1995 — Contrasting Neuroendocrine Responses in Depression and CFS (J AFFECT DISORD)

(Cleare et al. 1995)

Full Citation:: Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM, O’Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. Journal of Affective Disorders. 1995;34(4):283–289. DOI:: 10.1016/0165-0327(95)00026-j PMID:: 8550954 Study Design:: CFS vs major depression vs healthy comparison; d-fenfluramine challenge; matched for age, weight, sex, menstrual cycle Key Findings::

• Baseline cortisol highest in depression, lowest in CFS, intermediate in controls.
• Prolactin responses to d-fenfluramine were LOWEST in depressed, HIGHEST in CFS, intermediate in healthy (p=0.01).
• Matched-pair analysis confirmed higher prolactin responses in CFS vs controls. Conclusion:: Provides the key depression-vs-ME/CFS prolactin discrimination central to the topic — a challenge probe that can separate ME/CFS from depression on the basis of prolactin response. Limitations:: Small n per group (10 CFS, 15 depression); d-fenfluramine probe (not D2-blocking); single-center; Fukuda era. Certainty Assessment:: 0.62 raw × 1.00 ME/CFS-cohort weight = discounted 0.62

28 Demitrack 1997 — Neuroendocrine Correlates of CFS: A Brief Review (J PSYCHIATR RES)

(Demitrack 1997)

Full Citation:: Demitrack MA. Neuroendocrine correlates of chronic fatigue syndrome: a brief review. Journal of Psychiatric Research. 1997;31(1):69–82. DOI:: 10.1016/S0022-3956(96)00059-3 PMID:: 9201649 Study Design:: Narrative review of CFS neuroendocrine correlates (HPA axis + serotonergic challenge) Key Findings::

• Reviews HPA axis and serotonergic challenge findings in CFS, including prolactin responses.
• Situates the prolactin/serotonergic challenge literature within broader CFS neuroendocrinology and mood-disorder overlap. Conclusion:: Confirms the challenge-prolactin literature is small and mostly from the 1990s — consistent with the topic’s characterization as an ‘abandoned line.’ Limitations:: Review; 1990s era; predates modern ME/CFS diagnostic criteria. Certainty Assessment:: 0.60 raw × 1.00 ME/CFS-cohort weight = discounted 0.60

29 Ben-Jonathan & Hnasko 2001 — Dopamine as a Prolactin Inhibitor (ENDOCR REV; CANONICAL MECHANISM)

(Ben-Jonathan and Hnasko 2001)

Full Citation:: Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews. 2001;22(6):724–763. DOI:: 10.1210/edrv.22.6.0451 PMID:: 11739329 Study Design:: Authoritative physiology review of the dopamine–prolactin axis Key Findings::

• Dopamine reaches the pituitary via portal blood from hypothalamic tracts regulated by prolactin itself, estrogens, and neuropeptides.
• Dopamine binds type-2 dopamine (D2) receptors on lactotrophs to inhibit prolactin.
• Estrogens modulate both dopamine delivery and prolactin synthesis. Conclusion:: Supplies the core mechanism for candidate mechanism (a) (exaggerated prolactin response to a D2-blocking drug may reflect reduced dopaminergic inhibitory tone) and (b) (estradiol regulation of prolactin may contribute to female predominance). Limitations:: General physiology; not ME/CFS-specific. Certainty Assessment:: 0.85 raw × 0.75 general-population weight = discounted 0.64

30 Fitzgerald & Dinan 2008 — Prolactin and Dopamine: What Is the Connection? (J PSYCHOPHARMACOL)

(Fitzgerald and Dinan 2008)

Full Citation:: Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. Journal of Psychopharmacology. 2008;22(2 Suppl):12–19. DOI:: 10.1177/0269216307087148 PMID:: 18477617 Study Design:: Review of dopamine’s role in prolactin secretion Key Findings::

• Dopamine inhibits the basally high-secretory tone of lactotrophs via D2 receptors, reducing prolactin exocytosis and gene expression.
• Hypothalamic dopaminergic neurons are regulated by prolactin feedback (short loop). Conclusion:: Provides the pharmacologic basis for interpreting prolactin responses to D2-blocking or 5-HT1A-agonist challenges, including buspirone. Limitations:: General physiology; not ME/CFS-specific. Certainty Assessment:: 0.80 raw × 0.75 general-population weight = discounted 0.60

31 Qi-Lytle et al. 2023 — Current Review of Tuberoinfundibular Dopamine Neurons (INT J MOL SCI)

(Qi-Lytle, Sayers, and Wagner 2023)

Full Citation:: Qi-Lytle H, Sayers J, Wagner EJ. Current review of the function and regulation of tuberoinfundibular dopamine neurons. International Journal of Molecular Sciences. 2023;25(1):110. DOI:: 10.3390/ijms25010110 PMID:: 38203281 Study Design:: Modern physiology review of tuberoinfundibular dopamine (TIDA) neurons Key Findings::

• TIDA neurons project from the arcuate nucleus to the median eminence; portal dopamine activates D2 receptors to inhibit prolactin.
• TIDA neurons are the principal regulator of prolactin secretion.
• TIDA activity is modulated by estradiol, prolactin feedback, and metabolic signals. Conclusion:: Provides the current mechanistic framework for the proposed modern replication rationale — altered dopaminergic brake (candidate a) and estradiol modulation of TIDA/prolactin (candidate b). Limitations:: General physiology; not ME/CFS-specific. Certainty Assessment:: 0.80 raw × 0.75 general-population weight = discounted 0.60

32 Haghighi et al. 2021 — Monoamine Stabilizer (-)-OSU6162 in ME/CFS (BRAIN BEHAV; INDIRECT DOPAMINE LINK)

(Haghighi et al. 2021)

Full Citation:: Haghighi S, Forsmark J, Zachrisson O, Carlsson A, Nilsson M, Carlsson ML, Schuit RC, Gottfries CG. Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome. Brain and Behavior. 2021;11(4):e02040. DOI:: 10.1002/brb3.2040 PMID:: 33528911 Study Design:: Open-label trial of a dopamine (monoamine) stabilizer in ME/CFS Key Findings::

• Tests the hypothesis that dopaminergic dysfunction contributes to ME/CFS symptoms.
• Documents that dopaminergic modulation is being investigated as a treatment lever in ME/CFS. Conclusion:: Supports the general premise of dopaminergic dysregulation in ME/CFS relevant to the D2/prolactin mechanism. Limitations:: Open-label; small sample; no placebo control. Certainty Assessment:: 0.45 raw × 1.00 ME/CFS-cohort weight = discounted 0.45

33 Nochi et al. 2026 — REenergizeME: IHHT Protocol for ME/CFS (RCT) — ANCHOR

• Full Citation:: Nochi M, Kristensen SK, Mehrani N, et al. REenergizeME: intermittent hypoxia–hyperoxia treatment for myalgic encephalomyelitis/chronic fatigue syndrome—protocol for a randomised, placebo-controlled trial. BMJ Open. 2026;16:e117729. (Nochi et al. 2026)
• DOI:: 10.1136/bmjopen-2026-117729
• Study Design:: Randomised, placebo-controlled, participant- and assessor-blinded RCT protocol; 104 female ME/CFS (International Consensus Criteria), 20–59 y, mild–moderate (NICE), PEM documented, >6 months; 1:1 IHHT vs sham; 6 sessions over 8 weeks; HypoxBreath device (Telmed, CE IIa), 4–7 alternating hypoxia–hyperoxia cycles (SpO2 9–13% hypoxic, 36% hyperoxic); sham = room air with mimicked cues.
• Sample Size:: 104 ME/CFS (+ 20 healthy controls for mechanistic comparison).
• Key Findings::
  • Primary endpoint: SF-36 vitality domain change; effect assumption +20.5 vs placebo +6.8 (between-group 13.7) — extrapolated from a NON-controlled long-COVID IHHT cohort (Kapel2025).
  • Extensive secondary/exploratory: PEM (FUNCAP-27), fatigue (FSS), cognitive (d2-R), autonomic (COMPASS-31, NLT, Valsalva), pain (painDETECT), NIRS muscle oxygenation, handgrip, Sudoscan, thermal QST, corneal confocal microscopy, skin biopsy (IENFD, VIP/DbH, macrophages, mitochondria, microvasculature), PBMC flux/oxidative/inflammatory/metabolomic/proteomic/transcriptomic.
• Conclusion:: Protocol to test whether mild hormetic IHHT (HIF-1α preconditioning) improves QoL, PEM, fatigue, autonomic and microvascular function in ME/CFS. Results pending (recruitment Jun 2026; completion Jan 2029).
• Limitations:: Dose/regimen not ME/CFS-validated (no ME/CFS pilot); female-only; bedbound/very-severe underrepresented; power from non-controlled data; sham masking uncertain. Provenance/COI: shares investigators (Olsen RJ, Stokholm, Foldager, Nochi-family) AND device/protocol with the non-controlled Kapel2025 cohort used for the power calculation.
• Certainty Assessment::
  • Quality: High (peer-reviewed BMJ Open protocol; ICH-GCP)
  • Sample: Adequate (n=104 + controls)
  • Replication: N/A — results pending
  • Score: 0.95 (raw 0.95 × 1.00 ME/CFS weight; informational — design only, not efficacy)

34 Doehner et al. 2024 — IHHT During Inpatient Rehabilitation for Long COVID (Controlled Pilot) — PROTOCOL REF 39

• Full Citation:: Doehner W, Fischer A, Alimi B, Muhar J, Springer J, Altmann C, Schueller PO. Intermittent hypoxic–hyperoxic training during inpatient rehabilitation improves exercise capacity and functional outcome in patients with long covid: results of a controlled clinical pilot trial. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(6):2781–2791. (Doehner et al. 2024)
• DOI:: 10.1002/jcsm.13628
• Study Design:: Prospective, controlled, open-treatment (NON-randomized) pilot; 145 long-COVID inpatients (74% female, mean 53 y) in inpatient rehabilitation; 70 IHHT (10–12% O2 / 30–35% hyperoxic, 3×/week) + standard rehab vs 75 standard rehab.
• Sample Size:: 145 (70 IHHT vs 75 control).
• Key Findings::
  • 6MWT improved 2.8-fold vs control (91.7 vs 32.6 m, ANCOVA p<0.001).
  • Stair-climbing power improved 3.7-fold (-1.91 vs -0.51 s, p<0.001).
  • Dyspnoea, fatigue (FAS), QoL (PGA/EQ-5D/MCRS) improved; BP/HR decreased, haemoglobin increased (control unchanged).
  • No adverse events observed.
• Conclusion:: IHHT added to multidisciplinary rehabilitation improves functional capacity, symptomatic status and QoL in disabling long COVID; reported safe and well tolerated.
• Limitations:: Non-randomized, open-treatment (selection bias); single rehabilitation setting; no ME/CFS population; Germany (Charité/Median Klinikum) — independent of Danish REenergizeME team.
• Certainty Assessment::
  • Quality: Medium (controlled but non-randomized, open)
  • Sample: Moderate (n=145)
  • Replication: Single pilot
  • Score: 0.60 raw × 0.80 post-viral/long-COVID overlap weight = discounted 0.48

35 Kapel et al. 2025 — Individualized Algorithm-Based IHHC for Post-COVID (Open Cohort) — PROTOCOL REF 40

• Full Citation:: Kapel JS, Stokholm R, Elmengaard B, Nochi Z, Olsen RJ, Foldager CB. Individualized algorithm-based intermittent hypoxia improves quality of life in patients suffering from long-term sequelae after COVID-19 infection. Journal of Clinical Medicine. 2025;14(5):1590. (Kapel et al. 2025)
• DOI:: 10.3390/jcm14051590
• Study Design:: Open-label, NON-controlled cohort of individualized algorithm-based IHHC (SANA Therapy, HypoxBreath/INVATIO); 199 PCC patients (11–87 y, 67% female), moderate-severe fatigue, 2020–2023; mean 6 sessions (2–21); hypoxia 9–13% O2 3–8 min, hyperoxia 34–36% 1–3 min.
• Sample Size:: 199 PCC.
• Key Findings::
  • SF-36 increased ~102 points (p<0.001) at 6 weeks, ~106 at 6 months.
  • Pain reduced 28–32% (above clinically relevant threshold) at both time points.
  • No serious adverse events.
• Conclusion:: Personalized algorithm-based IHHC alleviated pain and improved QoL in long-term post-COVID sequelae, sustained to 6 months.
• Limitations:: Open, non-controlled; commercial-source data (SANA Medical Systems); authors Stokholm/Elmengaard/Foldager are co-founders/shareholders of SANA. Overlaps REenergizeME team (Olsen RJ, Stokholm, Foldager, Nochi Z) AND device/protocol; its SF-36 effect used for REenergizeME power calculation. No placebo control.
• Certainty Assessment::
  • Quality: Low-Medium (open cohort, no control, commercial)
  • Sample: Large (n=199) but non-controlled
  • Replication: Single cohort
  • Score: 0.35 raw × 0.80 post-viral weight, further COI/overlap-discounted = discounted 0.28

36 Zha et al. 2024 — Intermittent Hypoxia for Dyspnea and Fatigue in PASC (Controlled RCT) — PROTOCOL REF 41

• Full Citation:: Zha S, Liu X, Yao Y, et al. Short-term intermittent hypoxia exposure for dyspnea and fatigue in post-acute sequelae of COVID-19: a randomized controlled study. Respiratory Medicine. 2024;232:107763. (Zha et al. 2024)
• DOI:: 10.1016/j.rmed.2024.107763
• Study Design:: Prospective randomized controlled study (normoxia comparator + routine therapy; non-blinded); 95 PASC patients; 47 intermittent-hypoxia exposure (IHE; 5 min hypoxia / 5 min normal air ×5, mean 10 days) vs 48 normoxia exposure (NE). ChiCTR2300070565.
• Sample Size:: 95 (47 IHE vs 48 NE).
• Key Findings::
  • 6MWD, FVC, FEV1, VT, dyspnoea (Borg/mMRC), fatigue (FAS/CFQ-11) improved after IHE and greater than NE (all p<0.05).
  • ≥10 days of IHE > <10 days (6MWD, FVC, FEV1, VT, FAS, CFQ-11).
  • No severe adverse events.
• Conclusion:: Intermittent hypoxia (IHE) improved spirometry, 6MWD, dyspnoea and fatigue in PASC.
• Limitations:: This is intermittent-hypoxia (IHE), NOT IHHT (no hyperoxic phase); normoxia comparator (non-blinded); single center (Wuhan, China); no ME/CFS population; independent of Danish team.
• Certainty Assessment::
  • Quality: Medium (RCT but normoxia control, non-blinded, single center)
  • Sample: Moderate (n=95)
  • Replication: Single study
  • Score: 0.55 raw × 0.80 post-viral weight = discounted 0.44

37 Serebrovska et al. 2019 — IHHT vs Intermittent Hypoxia/Normoxia in Prediabetes (Placebo RCT)

• Full Citation:: Serebrovska TV, Grib ON, Portnichenko VI, Serebrovska ZO, Egorov E, Shatylo VB. Intermittent hypoxia/hyperoxia versus intermittent hypoxia/normoxia: comparative study in prediabetes. High Altitude Medicine & Biology. 2019;20(4):383–391. (Serebrovska et al. 2019)
• DOI:: 10.1089/ham.2019.0053
• Study Design:: Placebo-controlled RCT; 55 prediabetic patients (51–74 y); 17 IHHT (5 min 12% O2 / 3 min 33% O2), 22 IHT (hypoxia/normoxia), 16 sham; 3 weeks, 5×/week.
• Sample Size:: 55.
• Key Findings::
  • IHHT = IHT on fasting glucose, OGTT, LDL, cholesterol; equal improvement in hypoxic-test SpO2; persisted 1 month.
  • IHHT advantage: shorter reoxygenation periods (shorter sessions).
  • No adverse events reported.
• Conclusion:: IHHT is equivalent to IHT on metabolic endpoints in prediabetes, with session-time efficiency; establishes safety + physiological equivalence for IHHT dosing in a non-ME/CFS clinical population.
• Limitations:: Prediabetes population (not ME/CFS); single center (Ukraine); not powered for long-term outcomes.
• Certainty Assessment:: 0.55 raw × 0.60 non-ME/CFS clinical weight = discounted 0.33

38 Bestavashvili et al. 2022 — IHHE in Metabolic Syndrome (Sham-Controlled RCT)

• Full Citation:: Bestavashvili A, Glazachev O, Bestavashvili A, et al. Intermittent hypoxic-hyperoxic exposures effects in patients with metabolic syndrome: correction of cardiovascular and metabolic profile. Biomedicines. 2022;10(3):566. (Bestavashvili et al. 2022)
• DOI:: 10.3390/biomedicines10030566
• Study Design:: Randomized controlled study; 65 metabolic-syndrome patients on optimal pharmacotherapy; IHHE (3-wk, 5×/week, 45 min) vs sham (room air).
• Sample Size:: 65.
• Key Findings::
  • Corrected cardiovascular (SBP/DBP) and metabolic profile vs control.
  • No serious adverse events.
• Conclusion:: IHHE is safe and improves cardiovascular/metabolic profile in metabolic syndrome; physiological reference for IHHT dosing.
• Limitations:: Same cohort/trial as Afina2021 (companion analysis — do not double-count); non-ME/CFS population; Russia (Sechenov); short-term follow-up.
• Certainty Assessment:: 0.55 raw × 0.60 non-ME/CFS clinical weight = discounted 0.33

39 Afina et al. 2021 — IHHT Effects on Lipid Profile and Inflammation in Metabolic Syndrome (Companion)

• Full Citation:: Afina B, Oleg G, Alexander B, et al. The effects of intermittent hypoxic-hyperoxic exposures on lipid profile and inflammation in patients with metabolic syndrome. Frontiers in Cardiovascular Medicine. 2021;8:700826. (Afina et al. 2021)
• DOI:: 10.3389/fcvm.2021.700826
• Study Design:: Companion analysis (SAME Sechenov trial, n=65 metabolic syndrome, NCT04791397); IHHT vs sham.
• Key Findings::
  • Improved lipid profile (TC, LDL, TG) and anti-inflammatory status (decreased hs-CRP, Hsp70, NTproBNP, ALT/AST) vs sham.
  • No significant complications or serious adverse events.
• Conclusion:: IHHT improves lipid and inflammatory profile; safe and well tolerated as adjuvant treatment in metabolic syndrome.
• Limitations:: Cohort overlap with Bestavashvili2022 (same trial, different analyses — flagged); baseline group differences; non-ME/CFS population.
• Certainty Assessment:: 0.50 raw × 0.60 non-ME/CFS clinical weight = discounted 0.30 (overlap-flagged)

40 Zhang et al. 2023 — Intermittent Hypoxia Conditioning: Multi-Organ Protective Strategy (Mechanism Review)

• Full Citation:: Zhang Q, Zhao W, Li S, Ding Y, Wang Y, Ji X. Intermittent hypoxia conditioning: a potential multi-organ protective therapeutic strategy. International Journal of Medical Sciences. 2023;20(12):1551–1561. (Zhang et al. 2023)
• DOI:: 10.7150/ijms.86622
• Study Design:: Authoritative mechanism review (Xuanwu Hospital / Beijing Key Laboratory of Hypoxic Conditioning).
• Key Findings::
  • Intermittent hypoxia conditioning hormesis: calibrated mild-moderate hypoxia + appropriate cycles reduces oxidative stress, inflammation, apoptosis; enhances hypoxic gene expression (HIF-1α → erythropoiesis, angiogenesis, vascular regulation, metabolism).
  • Dose-dependent: low-dose hormetic IH = adaptive; excess = harmful.
• Conclusion:: Establishes the mechanism bridge between IHHT and the existing corpus hypoxia-altitude-hif1a stream (altitude/HIF-1α preconditioning); multi-organ protective therapeutic strategy.
• Limitations:: Review (not primary data); animal-model dominated; no direct ME/CFS evidence.
• Certainty Assessment:: 0.65 raw × 0.75 general-mechanism weight = discounted 0.49

41 Erdem et al. 2026 — Altered HIF-1α/Netrin in OSA: Pathological Intermittent Hypoxia (Harm Contrast)

• Full Citation:: Erdem M, Kıran TR, Kırıcı Berber N, Şahin Gür L, Erdem Ş. Altered HIF-1α, Netrin-1, and Netrin-4 levels in obstructive sleep apnea: associations with intermittent hypoxia and disease severity. Medicina (Kaunas). 2026;62(7):1340. (Erdem et al. 2026)
• DOI:: 10.3390/medicina62071340
• Study Design:: Case-control; 52 OSA + 26 controls; serum HIF-1α, Netrin-1, Netrin-4 by ELISA; regression adjusted for BMI/age/CRP/LDL.
• Key Findings::
  • Serum HIF-1α, Netrin-1, Netrin-4 progressively elevated with OSA severity (p<0.0001), independent of BMI/age/CRP/LDL.
• Conclusion:: Chronic pathological intermittent hypoxia (OSA) drives persistent HIF-1α elevation + oxidative stress — the pathological pole contrasting with the mild transient-HIF-1α preconditioning that IHHT (brief, low-frequency cycles) aims for.
• Limitations:: OSA (disease) population, not IHHT; no direct ME/CFS relevance; used to bound the mild-hormetic vs pathological-chronic IH distinction.
• Certainty Assessment:: 0.55 raw × 0.60 general-harm-contrast weight = discounted 0.33

42 She et al. 2026 — Differential CV/Autonomic Responses to IH Paradigms in Rats (Harm/Mechanism)

• Full Citation:: She SC, Lin CW, Chen CW, et al. Differential cardiovascular and autonomic responses to structurally distinct intermittent hypoxia paradigms in rats. Hypertension Research. 2026;49(5):1659–1672. (She et al. 2026)
• DOI:: 10.1038/s41440-026-02588-7
• Study Design:: Experimental rat study comparing structurally distinct intermittent hypoxia paradigms at equal cumulative burden.
• Key Findings::
  • The duration + frequency of desaturation-reoxygenation cycles produce distinct cardiovascular + autonomic outcomes even at equal cumulative burden.
• Conclusion:: Supports the mild-hormetic (brief, well-spaced cycles — IHHT) vs pathological (high-frequency sustained desaturation — OSA) dosing distinction central to IHHT safety.
• Limitations:: Animal data; mechanistic; not direct clinical evidence; no ME/CFS.
• Certainty Assessment:: 0.50 raw × 0.50 animal-to-human relevance = discounted 0.25

43 Gherardi et al. 2019 — Myalgia and CFS Following Immunization: MMF and Aluminum Adjuvant Persistency (ASIA Core Thesis)

• Full Citation:: Gherardi RK, Crépeaux G, Authier FJ. Myalgia and chronic fatigue syndrome following immunization: macrophages myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. Autoimmunity Reviews. 2019;18(7):691–705. (Gherardi, Crépeaux, and Authier 2019)
• DOI:: 10.1016/j.autrev.2019.05.006
• Study Design:: Narrative review (Henri-Mondor group, Gherardi/Authier).
• Key Findings::
  • Argues ME/CFS is a major adverse effect of vaccines with poorly degradable particulate aluminum adjuvants.
  • MMF is a histological biomarker of persistent aluminum in innate immune cells at the injection site.
  • MMF represents the core manifestation of ASIA; cites Gulf War II vaccinated-vs-unvaccinated military epidemiology and sheep experiments.
• Conclusion:: Proposes chronic immune stimulation by persisting aluminum adjuvants as a causal route to post-immunization ME/CFS.
• Limitations:: Single-group thesis; no independent replication of the MMF→ME/CFS link; registry counter-evidence (Magnus2015) not reconciled.
• Certainty Assessment:: 0.55 raw × 0.75 general-pop/symptom-defined weight = discounted 0.41

44 Rigolet et al. 2014 — Clinical Features in Long-Lasting Macrophagic Myofasciitis

• Full Citation:: Rigolet M, Aouizerate J, Couette M, et al. Clinical features in patients with long-lasting macrophages myofasciitis. Frontiers in Neurology. 2014;5:230. (Rigolet et al. 2014)
• DOI:: 10.3389/fneur.2014.00230
• Study Design:: Clinical case series (Garches–Necker–Mondor–Hendaye referral center).
• Sample Size:: MMF cohort (~70; Henri-Mondor referral cohort).
• Key Findings::
  • MMF patients present with diffuse arthromyalgias, chronic fatigue, and cognitive deficits (dysexecutive syndrome, visual memory impairment, left-ear extinction).
  • Clinical features described as “corresponding to” CFS/ME; most meet non-amnestic/dysexecutive MCI.
• Conclusion:: MMF is associated with a chronic fatigue + cognitive phenotype overlapping ME/CFS.
• Limitations:: COHORT OVERLAP — same Henri-Mondor referral cohort as other MMF papers (not independent); no formal ME/CFS diagnostic-criteria (Fukuda/CCC/ICC/IOM) application.
• Certainty Assessment:: 0.55 raw × 0.80 fibro/comorbid-like MMF weight = discounted 0.44

45 Van Der Gucht et al. 2015 — Brain Perfusion SPECT Correlates of Cognitive Dysfunction in MMF

• Full Citation:: Van Der Gucht A, Aoun Sebaiti M, Itti E, et al. Neuropsychological correlates of brain perfusion SPECT in patients with macrophages myofasciitis. PLoS ONE. 2015;10(6):e0128353. (Van Der Gucht et al. 2015)
• DOI:: 10.1371/journal.pone.0128353
• Study Design:: Cross-sectional brain imaging + neuropsychology.
• Sample Size:: 76 consecutive MMF patients (aged 49±10).
• Key Findings::
  • Executive-function scores positively correlate with posterior associative cortex perfusion; negative correlation with amygdalo-hippocampal complexes.
  • Supports a brain-perfusion correlate of MMF cognitive complaints.
• Conclusion:: MMF cognitive dysfunction has a reproducible brain-perfusion correlate.
• Limitations:: COHORT OVERLAP (Henri-Mondor); no ME/CFS comparator group; no formal diagnostic criteria; referral bias.
• Certainty Assessment:: 0.60 raw × 0.80 fibro/comorbid weight = discounted 0.48

46 Van Der Gucht et al. 2017 — Brain ¹⁸F-FDG PET in Long-Lasting MMF

• Full Citation:: Van Der Gucht A, Aoun Sebaiti M, Guedj E, et al. Brain ¹⁸F-FDG PET metabolic abnormalities in patients with long-lasting macrophages myofascitis. Journal of Nuclear Medicine. 2017;58(3):492–498. (Van Der Gucht et al. 2017)
• DOI:: 10.2967/jnumed.114.151878
• Study Design:: Cross-sectional FDG-PET imaging.
• Sample Size:: MMF cohort (Henri-Mondor).
• Key Findings::
  • Distinctive cerebral glucose hypometabolism pattern in long-lasting MMF.
  • Claims a CNS metabolic signature that may distinguish MMF.
• Conclusion:: MMF is associated with a characteristic brain-hypometabolism pattern.
• Limitations:: COHORT OVERLAP; no ME/CFS comparator; no replication; single referral center.
• Certainty Assessment:: 0.55 raw × 0.80 fibro/comorbid weight = discounted 0.44

47 Aoun Sebaiti et al. 2018 — Reappraisal of the Neuropsychological Profile in MMF

• Full Citation:: Aoun Sebaiti M, Kauv P, Charles-Nelson A, et al. Cognitive dysfunction associated with aluminum hydroxide-induced macrophages myofasciitis: a reappraisal of neuropsychological profile. Journal of Inorganic Biochemistry. 2018;181:132–138. (Aoun Sebaiti et al. 2018)
• DOI:: 10.1016/j.jinorgbio.2017.09.019
• Study Design:: Cross-sectional neuropsychological reappraisal.
• Sample Size:: MMF cohort (Henri-Mondor).
• Key Findings::
  • Documents chronic fatigue and cognitive disorder with representative dysexecutive and memory features in MMF.
• Conclusion:: MMF cognitive profile is consistent and reproducible within the cohort.
• Limitations:: COHORT OVERLAP; no independent replication; no ME/CFS diagnostic-criteria application.
• Certainty Assessment:: 0.50 raw × 0.80 fibro/comorbid weight = discounted 0.40

48 Gherardi et al. 2015 — Biopersistence and Brain Translocation of Aluminum Adjuvants (Mechanism)

• Full Citation:: Gherardi RK, Eidi H, Crépeaux G, Authier FJ, Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Frontiers in Neurology. 2015;6:4. (Gherardi et al. 2015)
• DOI:: 10.3389/fneur.2015.00004
• Study Design:: Mechanism review (Henri-Mondor group).
• Key Findings::
  • Aluminum adjuvants biopersist within phagocytes and translocate to distant organs and brain.
  • Elicit an inflammatory response and selective low-dose long-term neurotoxicity in experimental animals.
• Conclusion:: Mechanistic basis for a chronic immune-stimulation + neuroinflammation route from aluminum adjuvants.
• Limitations:: Single-group mechanistic claim; animal-based for brain effects; translation gap.
• Certainty Assessment:: 0.60 raw × 0.75 general/mechanism weight = discounted 0.45

49 Crépeaux et al. 2017 — Non-Linear Dose-Response: Low-Dose Aluminum Adjuvant Neurotoxicity (Animal)

• Full Citation:: Crépeaux G, Eidi H, David MO, et al. Non-linear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity. Toxicology. 2017;375:12–25. (Crépeaux et al. 2017)
• DOI:: 10.1016/j.tox.2016.11.018
• Study Design:: Rodent toxicology (experimental).
• Key Findings::
  • Non-monotonic dose-response of aluminium hydroxide adjuvant particles.
  • Selective neurotoxicity at low dose (effects missed by conventional high-dose toxicology).
• Conclusion:: Supports the claim that low-dose, long-term aluminum adjuvant effects are under-detected.
• Limitations:: Animal model (cross-species gap); single group; not ME/CFS-specific.
• Certainty Assessment:: 0.55 raw × 0.50 animal-to-human relevance = discounted 0.28

50 Masson et al. 2024 — Phagocyte Immuno-Metabolic Responses in MMF (In Vitro)

• Full Citation:: Masson JD, Badran G, Gherardi RK, Authier FJ, Crépeaux G. Widespread myalgia and chronic fatigue: phagocytes from macrophages myofasciitis patients exposed to aluminum oxyhydroxide-adjuvanted vaccine exhibit specific inflammatory, autophagic, and mitochondrial responses. Toxics. 2024;12(7):491. (Masson et al. 2024)
• DOI:: 10.3390/toxics12070491
• Study Design:: In vitro study of patient-derived MMF phagocytes vs controls.
• Key Findings::
  • MMF phagocytes express Rubicon and Nox2 (LC3-associated phagocytosis machinery).
  • They produce pain-inducing CXC chemokines, less TNF-α, and show mitochondrial dysfunction (limited spare respiratory capacity, proton leak) on vaccine exposure.
• Conclusion:: MMF cells show an immune-exhausted, pain-promoting, energetically compromised phenotype consistent with chronic myalgia and fatigue.
• Limitations:: In vitro (no organism-level validation); single group; ME/CFS inference indirect.
• Certainty Assessment:: 0.55 raw × 0.40 in-vitro weight = discounted 0.22

51 Eisenbarth et al. 2008 — Nalp3/NLRP3 Inflammasome Activation by Alum (Mechanism)

• Full Citation:: Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–1126. (Eisenbarth et al. 2008)
• DOI:: 10.1038/nature06939
• Study Design:: Foundational immunology (rodent + in vitro).
• Key Findings::
  • Aluminium adjuvants activate the Nalp3/NLRP3 inflammasome → IL-1β production, independent of Toll-like receptor signalling.
  • Establishes the canonical mechanistic basis for aluminum as a pro-inflammatory, immune-stimulating agent.
• Conclusion:: Aluminum adjuvants are bona fide NLRP3 inflammasome agonists — a plausible chronic-immune-stimulation vector.
• Limitations:: Cell/animal level; does not establish ME/CFS relevance.
• Certainty Assessment:: 0.70 raw × 0.40 in-vitro weight = discounted 0.28

52 Principi & Esposito 2018 — Aluminum in Vaccines: Safety Counter-Review (Independent)

• Full Citation:: Principi N, Esposito S. Aluminum in vaccines: does it create a safety problem? Vaccine. 2018;36(39):5825–5831. (Principi and Esposito 2018)
• DOI:: 10.1016/j.vaccine.2018.08.036
• Study Design:: Narrative safety review (independent of Gherardi group).
• Key Findings::
  • No evidence that aluminum in vaccines accumulates to pathological levels causing systemic disease from routine immunization.
  • MMF regarded as a rare, usually benign local reaction; does not support a causal link to ME/CFS.
• Conclusion:: Rejects the aluminum-adjuvant → ME/CFS causal claim on available safety data.
• Limitations:: Narrative review (no new data); general-population framing.
• Certainty Assessment:: 0.60 raw × 0.75 general-population weight = discounted 0.45

53 Mitkus et al. 2011 — FDA Aluminum Pharmacokinetics (Regulatory Counter-Evidence)

• Full Citation:: Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011;29(51):9538–9543. (Mitkus et al. 2011)
• DOI:: 10.1016/j.vaccine.2011.09.124
• Study Design:: Regulatory pharmacokinetic modelling (US FDA CBER).
• Key Findings::
  • Cumulative aluminum from diet + routine infant vaccination remains below established toxic thresholds.
  • Does not accumulate to a harmful body burden.
• Conclusion:: Authoritative regulatory counter to the “aluminum overload” claim underpinning the MMF hypothesis.
• Limitations:: Pharmacokinetic modelling (general-population); does not directly address MMF pathology.
• Certainty Assessment:: 0.70 raw × 0.75 general-population weight = discounted 0.53

54 Perez et al. 2026 — Independent NLRP3-Alum Mechanism (NLRP3-Independent Effects In Vivo)

• Full Citation:: Perez DC, Hernandez-Franco JF, HogenEsch H. Aluminum adjuvants differentially induce IL-1β release in vitro yet share NLRP3 inflammasome-independent adjuvant effects in vivo. Scientific Reports. 2026;16(1):4570. (Perez, Hernandez-Franco, and HogenEsch 2026)
• DOI:: 10.1038/s41598-025-34660-6
• Study Design:: Mechanistic (human/mouse macrophages and dendritic cells; rodent in vivo).
• Key Findings::
  • Aluminum phosphate (AP) induces more IL-1β than aluminum hydroxide (AH) via NLRP3-dependent pro-IL-1β proteolysis.
  • Adjuvant effects can be NLRP3-independent in vivo — nuancing the “alum acts purely via NLRP3/IL-1β” claim.
• Conclusion:: Independent (non-Gherardi) evidence that the NLRP3/IL-1β pathway is not the sole aluminum-adjuvant mechanism.
• Limitations:: In vitro + rodent; not ME/CFS-specific; recent, limited replication.
• Certainty Assessment:: 0.55 raw × 0.40 in-vitro weight = discounted 0.22

References

Afina, Bestavashvili, Glazachev Oleg, Bestavashvili Alexander, Dossantos Ines, Yu Alexander, Vedenkin Nikita, Stepanov Denis, et al. 2021. “The Effects of Intermittent Hypoxic-Hyperoxic Exposures on Lipid Profile and Inflammation in Patients with Metabolic Syndrome.” Frontiers in Cardiovascular Medicine 8: 700826. https://doi.org/10.3389/fcvm.2021.700826.

Aoun Sebaiti, Mouna, Paul Kauv, Anouk Charles-Nelson, Axel Van Der Gucht, Paul Blanc-Durand, Emmanuel Itti, Romain K Gherardi, Anne-Catherine Bachoud-Levi, and François-Jérôme Authier. 2018. “Cognitive Dysfunction Associated with Aluminum Hydroxide-Induced Macrophages Myofasciitis: A Reappraisal of Neuropsychological Profile.” Journal of Inorganic Biochemistry 181: 132–38. https://doi.org/10.1016/j.jinorgbio.2017.09.019.

Arjunan, Darshana, Taruna Bhadada, Siddharth S Mohankumar, and Sanjay K Bhadada. 2023. “Non-Biological Antiresorptive: Bisphosphonates.” Indian Journal of Orthopaedics 57 (Suppl 1): 120–26. https://doi.org/10.1007/s43465-023-01054-7.

Bakheit, A M O, P O Behan, T G Dinan, C E Gray, and V O’Keane. 1992. “Possible Upregulation of Hypothalamic 5-Hydroxytryptamine Receptors in Patients with Postviral Fatigue Syndrome.” BMJ 304 (6833): 1010–12. https://doi.org/10.1136/bmj.304.6833.1010.

Bearn, J, T Allain, P Coskeran, N Munro, J Butler, A McGregor, and S Wessely. 1995. “Neuroendocrine Responses to d-Fenfluramine and Insulin-Induced Hypoglycemia in Chronic Fatigue Syndrome.” Biological Psychiatry 37 (4): 245–52. https://doi.org/10.1016/0006-3223(94)00121-i.

Ben-Jonathan, N, and R Hnasko. 2001. “Dopamine as a Prolactin (PRL) Inhibitor.” Endocrine Reviews 22 (6): 724–63. https://doi.org/10.1210/edrv.22.6.0451.

Bestavashvili, Akulina, Oleg Glazachev, Alexander Bestavashvili, Alexander Suvorov, Yulong Zhang, Xiaoyun Zhang, Alexander Rozhkov, et al. 2022. “Intermittent Hypoxic-Hyperoxic Exposures Effects in Patients with Metabolic Syndrome: Correction of Cardiovascular and Metabolic Profile.” Biomedicines 10 (3): 566. https://doi.org/10.3390/biomedicines10030566.

Bolland, Mark J, Alison Avenell, John A Baron, Andrew Grey, Graeme S MacLennan, Gregory D Gamble, and Ian R Reid. 2010. “Effect of Calcium Supplements on Risk of Myocardial Infarction and Cardiovascular Events: Meta-Analysis.” BMJ 341: c3691. https://doi.org/10.1136/bmj.c3691.

Cleare, A J, J Bearn, T Allain, A McGregor, S Wessely, R M Murray, and V O’Keane. 1995. “Contrasting Neuroendocrine Responses in Depression and Chronic Fatigue Syndrome.” Journal of Affective Disorders 34 (4): 283–89. https://doi.org/10.1016/0165-0327(95)00026-j.

Cleare, A J, and V O’Keane. 1996. “Re: Endocrine Responses to Fenfluramine Challenge in Chronic Fatigue Syndrome.” Canadian Journal of Psychiatry 41 (2): 129–31.

Crépeaux, Géraldine, Hélène Eidi, Marie-Odile David, Eleni Tzavara, Bruno Giros, Christopher Exley, Josette Cadusseau, François-Jérôme Authier, and Romain K Gherardi. 2017. “Non-Linear Dose-Response of Aluminium Hydroxide Adjuvant Particles: Selective Low Dose Neurotoxicity.” Toxicology 375: 12–25. https://doi.org/10.1016/j.tox.2016.11.018.

Demitrack, M A. 1997. “Neuroendocrine Correlates of Chronic Fatigue Syndrome: A Brief Review.” Journal of Psychiatric Research 31 (1): 69–82. https://doi.org/10.1016/S0022-3956(96)00059-3.

Dinan, T G, L V Scott, J Thakore, J Naesdal, and P W Keeling. 2001. “Impact of Cortisol on Buspirone Stimulated Prolactin Release: A Double-Blind Placebo-Controlled Study.” Psychoneuroendocrinology 26 (7): 751–56. https://doi.org/10.1016/S0306-4530(01)00029-4.

Doehner, Wolfram, Annette Fischer, Bernhard Alimi, Josef Muhar, Jochen Springer, Christian Altmann, and Per Otto Schueller. 2024. “Intermittent Hypoxic–Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients with Long Covid: Results of a Controlled Clinical Pilot Trial.” Journal of Cachexia, Sarcopenia and Muscle 15 (6): 2781–91. https://doi.org/10.1002/jcsm.13628.

Earl, Katie E, Giorgos K Sakellariou, Mary Sinclair, Mark Fenech, Fiona Croden, Daniel J Owens, Jonathan Tang, et al. 2017. “Vitamin d Status in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Cohort Study from the North-West of England.” BMJ Open 7 (11): e015296. https://doi.org/10.1136/bmjopen-2016-015296.

Eisenbarth, Stephanie C, Oscar R Colegio, William O’Connor, Fayyaz S Sutterwala, and Richard A Flavell. 2008. “Crucial Role for the Nalp3 Inflammasome in the Immunostimulatory Properties of Aluminium Adjuvants.” Nature 453 (7198): 1122–26. https://doi.org/10.1038/nature06939.

El-Tawil, Salwa, Tariq Al Musa, Hassan Valli, Michael P. Lunn, Tarek El-Tawil, and Markus Weber. 2010. “Quinine for Muscle Cramps.” Cochrane Database of Systematic Reviews, no. 12: CD005044. https://doi.org/10.1002/14651858.CD005044.pub2.

Erdem, Mustafa, Tülin Rana Kıran, Nefise Kırıcı Berber, Leila Şahin Gür, and Şule Erdem. 2026. “Altered HIF-1\(\alpha\), Netrin-1, and Netrin-4 Levels in Obstructive Sleep Apnea: Associations with Intermittent Hypoxia and Disease Severity.” Medicina (Kaunas) 62 (7): 1340. https://doi.org/10.3390/medicina62071340.

Fitzgerald, P, and T G Dinan. 2008. “Prolactin and Dopamine: What Is the Connection? A Review Article.” Journal of Psychopharmacology 22 (2 Suppl): 12–19. https://doi.org/10.1177/0269216307087148.

Gherardi, Romain K, Géraldine Crépeaux, and François-Jérôme Authier. 2019. “Myalgia and Chronic Fatigue Syndrome Following Immunization: Macrophages Myofasciitis and Animal Studies Support Linkage to Aluminum Adjuvant Persistency and Diffusion in the Immune System.” Autoimmunity Reviews 18 (7): 691–705. https://doi.org/10.1016/j.autrev.2019.05.006.

Gherardi, Romain K, Hélène Eidi, Géraldine Crépeaux, François-Jérôme Authier, and Josette Cadusseau. 2015. “Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines.” Frontiers in Neurology 6: 4. https://doi.org/10.3389/fneur.2015.00004.

Haeusler, Isabella L., Xin Hui S. Chan, Philippe J. Guérin, and Nicholas J. White. 2018. “The Arrhythmogenic Cardiotoxicity of the Quinoline and Structurally Related Antimalarial Drugs: A Systematic Review.” BMC Medicine 16 (1): 200. https://doi.org/10.1186/s12916-018-1188-2.

Haghighi, S, J Forsmark, O Zachrisson, A Carlsson, M Nilsson, M L Carlsson, R C Schuit, and C G Gottfries. 2021. “Open-Label Study with the Monoamine Stabilizer (-)-OSU6162 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Brain and Behavior 11 (4): e02040. https://doi.org/10.1002/brb3.2040.

Hart, David A. 2021. “Learning from Human Responses to Deconditioning Environments: Improved Understanding of the "Use It or Lose It" Principle.” Frontiers in Sports and Active Living 3: 685845. https://doi.org/10.3389/fspor.2021.685845.

Hawke, Fiona, Sean G. Sadler, Hans D. Katzberg, Fereshteh Pourkazemi, Vivienne Chuter, and Joshua Burns. 2021. “Non-Drug Therapies for the Secondary Prevention of Lower Limb Muscle Cramps.” Cochrane Database of Systematic Reviews, no. 5: CD008496. https://doi.org/10.1002/14651858.CD008496.pub3.

Kapel, Jesper Sørensen, Rasmus Stokholm, Brian Elmengaard, Zahra Nochi, Rikke Katrine Jentoft Olsen, and Casper Bindzus Foldager. 2025. “Individualized Algorithm-Based Intermittent Hypoxia Improves Quality of Life in Patients Suffering from Long-Term Sequelae After COVID-19 Infection.” Journal of Clinical Medicine 14 (5): 1590. https://doi.org/10.3390/jcm14051590.

Liles, Nathan W., Elizabeth E. Page, Alexander L. Liles, Sara K. Vesely, Gary E. Raskob, and James N. George. 2016. “Diversity and Severity of Adverse Reactions to Quinine: A Systematic Review.” American Journal of Hematology 91 (5): 461–66. https://doi.org/10.1002/ajh.24314.

Man-Son-Hing, Malcolm, and George Wells. 1995. “Meta-Analysis of Efficacy of Quinine for Treatment of Nocturnal Leg Cramps in Elderly People.” BMJ 310 (6971): 13–17.

Man-Son-Hing, Malcolm, George Wells, and Andy Lau. 1998. “Quinine for Nocturnal Leg Cramps: A Meta-Analysis Including Unpublished Data.” Journal of General Internal Medicine 13 (9): 600–606.

Masson, Jean-Daniel, Gherici Badran, Romain K Gherardi, François-Jérôme Authier, and Géraldine Crépeaux. 2024. “Widespread Myalgia and Chronic Fatigue: Phagocytes from Macrophages Myofasciitis Patients Exposed to Aluminum Oxyhydroxide-Adjuvanted Vaccine Exhibit Specific Inflammatory, Autophagic, and Mitochondrial Responses.” Toxics 12 (7): 491. https://doi.org/10.3390/toxics12070491.

Mitkus, Robert J, David B King, Marie A Hess, Richard A Forshee, and Mark O Walderhaug. 2011. “Updated Aluminum Pharmacokinetics Following Infant Exposures Through Diet and Vaccination.” Vaccine 29 (51): 9538–43. https://doi.org/10.1016/j.vaccine.2011.09.124.

Newman, M E, B Shapira, and B Lerer. 1998. “Evaluation of Central Serotonergic Function in Affective and Related Disorders by the Fenfluramine Challenge Test: A Critical Review.” The International Journal of Neuropsychopharmacology 1 (1): 49–69. https://doi.org/10.1017/S1461145798001072.

Nochi, Mastaneh, Sophie Kjerstein Kristensen, Niloufar Mehrani, Inês Guerreiro, Ida Marie Dahl Nørholm, Shreyas Chandra, Mette Olufsen, et al. 2026. “REenergizeME: Intermittent Hypoxia–Hyperoxia Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome—Protocol for a Randomised, Placebo-Controlled Trial.” BMJ Open 16: e117729. https://doi.org/10.1136/bmjopen-2026-117729.

Perez, Daniel C, Juan F Hernandez-Franco, and Harm HogenEsch. 2026. “Aluminum Adjuvants Differentially Induce IL-1\(\beta\) Release in Vitro yet Share NLRP3 Inflammasome-Independent Adjuvant Effects in Vivo.” Scientific Reports 16 (1): 4570. https://doi.org/10.1038/s41598-025-34660-6.

Principi, Nicola, and Susanna Esposito. 2018. “Aluminum in Vaccines: Does It Create a Safety Problem?” Vaccine 36 (39): 5825–31. https://doi.org/10.1016/j.vaccine.2018.08.036.

Qi-Lytle, H, J Sayers, and E J Wagner. 2023. “Current Review of the Function and Regulation of Tuberoinfundibular Dopamine Neurons.” International Journal of Molecular Sciences 25 (1): 110. https://doi.org/10.3390/ijms25010110.

Qin, Weiping, Li Sun, Jing Cao, Yuanzhen Peng, Lauren Collier, Yan Wu, Graham Creasey, et al. 2013. “The Central Nervous System (CNS)-Independent Anti-Bone-Resorptive Activity of Muscle Contraction and the Underlying Molecular and Cellular Signatures.” Journal of Biological Chemistry 288 (19): 13511–21. https://doi.org/10.1074/jbc.M113.454892.

Rigolet, Muriel, Jérôme Aouizerate, Marie Couette, Nalini Ragunathan-Thangarajah, Mouna Aoun-Sebaiti, Romain K Gherardi, Josette Cadusseau, and François-Jérôme Authier. 2014. “Clinical Features in Patients with Long-Lasting Macrophages Myofasciitis.” Frontiers in Neurology 5: 230. https://doi.org/10.3389/fneur.2014.00230.

Rolvien, Tim, and Michael Amling. 2022. “Disuse Osteoporosis: Clinical and Mechanistic Insights.” Calcified Tissue International 110 (5): 592–604. https://doi.org/10.1007/s00223-021-00836-1.

Serebrovska, Tetyana V, Olena N Grib, Victor I Portnichenko, Zoia O Serebrovska, Evgeny Egorov, and Valery B Shatylo. 2019. “Intermittent Hypoxia/Hyperoxia Versus Intermittent Hypoxia/Normoxia: Comparative Study in Prediabetes.” High Altitude Medicine & Biology 20 (4): 383–91. https://doi.org/10.1089/ham.2019.0053.

Shane, Elizabeth, David Burr, Bo Abrahamsen, Robert A Adler, Thomas D Brown, Angela M Cheung, Felicia Cosman, et al. 2014. “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research.” Journal of Bone and Mineral Research 29 (1): 1–23. https://doi.org/10.1002/jbmr.1998.

Sharma, A, F Oyebode, M J Kendall, and P W Jones. 2001. “Recovery from Chronic Fatigue Syndrome Associated with Changes in Neuroendocrine Function.” Journal of the Royal Society of Medicine 94 (1): 26–27. https://doi.org/10.1177/014107680109400107.

Sharpe, M, A Clements, K Hawton, A H Young, P Sargent, and P J Cowen. 1996. “Increased Prolactin Response to Buspirone in Chronic Fatigue Syndrome.” Journal of Affective Disorders 41 (1): 71–76. https://doi.org/10.1016/0165-0327(96)00075-4.

She, Shih-Chieh, Chun-Wen Lin, Chia-Wei Chen, Chin-Hsiung Wu, Shang-Syue Huang, Chih-Jung Lai, Terry B J Kuo, et al. 2026. “Differential Cardiovascular and Autonomic Responses to Structurally Distinct Intermittent Hypoxia Paradigms in Rats.” Hypertension Research 49 (5): 1659–72. https://doi.org/10.1038/s41440-026-02588-7.

Spillane, J., J. Trip, G. Drost, C. G. Faber, M. G. Hanna, S. J. Nevitt, and V. Vivekanandam. 2025. “Drug Treatment for Myotonia.” Cochrane Database of Systematic Reviews, no. 4: CD004762. https://doi.org/10.1002/14651858.CD004762.pub3.

Taylor, Alexander D, and Kenneth G Saag. 2019. “Anabolics in the Management of Glucocorticoid-Induced Osteoporosis: An Evidence-Based Review of Long-Term Safety, Efficacy and Place in Therapy.” Core Evidence 14: 41–50. https://doi.org/10.2147/CE.S172820.

Torbergsen, Torberg, Karin Jurkat-Rott, Erik V. Stålberg, Sissel Løseth, Ase Hødneø, and Frank Lehmann-Horn. 2015. “Painful Cramps and Giant Myotonic Discharges in a Family with the Nav1.4-G1306A Mutation.” Muscle & Nerve 52 (4): 680–83. https://doi.org/10.1002/mus.24672.

Van Der Gucht, Axel, Mouna Aoun Sebaiti, Eric Guedj, Jérôme Aouizerate, Sarah Yara, Romain K Gherardi, Evangelia Evangelista, et al. 2017. “Brain (^18f)-FDG PET Metabolic Abnormalities in Patients with Long-Lasting Macrophages Myofascitis.” Journal of Nuclear Medicine 58 (3): 492–98. https://doi.org/10.2967/jnumed.114.151878.

Van Der Gucht, Axel, Mouna Aoun Sebaiti, Emmanuel Itti, Jérôme Aouizerate, Evangelia Evangelista, Julia Chalaye, Romain K Gherardi, Nalini Ragunathan-Thangarajah, Anne-Catherine Bachoud-Levi, and François-Jérôme Authier. 2015. “Neuropsychological Correlates of Brain Perfusion SPECT in Patients with Macrophages Myofasciitis.” PLoS ONE 10 (6): e0128353. https://doi.org/10.1371/journal.pone.0128353.

White, Nicholas J. 2007. “Cardiotoxicity of Antimalarial Drugs.” The Lancet Infectious Diseases 7 (8): 549–58.

Yatham, L N, R L Morehouse, B T Chisholm, D A Haase, D D MacDonald, and T J Marrie. 1995. “Neuroendocrine Assessment of Serotonin (5-HT) Function in Chronic Fatigue Syndrome.” Canadian Journal of Psychiatry 40 (2): 93–96. https://doi.org/10.1177/070674379504000207.

Young, Gavin. 2009. “Leg Cramps.” BMJ Clinical Evidence, 1113.

Zha, Song, Xiang Liu, Yun Yao, Yiyang He, Yuxin Wang, Qing Zhang, Jie Zhang, Yuan Yi, Rui Xiao, and Ke Hu. 2024. “Short-Term Intermittent Hypoxia Exposure for Dyspnea and Fatigue in Post-Acute Sequelae of COVID-19: A Randomized Controlled Study.” Respiratory Medicine 232: 107763. https://doi.org/10.1016/j.rmed.2024.107763.

Zhang, Qian, Wenbo Zhao, Shu Li, Yuchuan Ding, Yinsheng Wang, and Xunming Ji. 2023. “Intermittent Hypoxia Conditioning: A Potential Multi-Organ Protective Therapeutic Strategy.” International Journal of Medical Sciences 20 (12): 1551–61. https://doi.org/10.7150/ijms.86622.